Last update March 19, 2024

维拉卡肽

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Ethelcalcetide is a synthetic peptide agonist of the calcium-sensing receptors of the parathyroid gland that decreases parathyroid hormone secretion and serum calcium concentration.  It has a mechanism of action similar to cinacalcet. It is used to treat secondary hyperparathyroidism in patients with chronic kidney disease requiring hemodialysis. Intravenous administration three times a week or at the end of each dialysis session.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (large volume of distribution, moderately high molecular weight and its binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.

Alternatives

  • Alendronate Sodium (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Calcitriol (Safe product and/or breastfeeding is the best option.)
  • Pamidronate Disodium (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

维拉卡肽 is Etelcalcetide in Chinese.

Is written in other languages:

维拉卡肽 is also known as

Group

维拉卡肽 belongs to this group or family:

Tradenames

Main tradenames from several countries containing 维拉卡肽 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 1.048 daltons
Protein Binding 99.4? %
VD 11.4 l/Kg
Tmax 0.22 hours
T½ 72 - 96 hours

References

  1. Xing C, Chen J, Zuo L, Fang Y, Ding X, Ni Z, Kong C, Shi G, Lu H, Hellawell J, Cheng S, Sohn W. A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis. Clin Ther. 2021 Nov;43(11):2013-2023. Abstract Full text (link to original source)
  2. Wu B, Melhem M, Subramanian R, Chen P, Jaramilla Sloey B, Fouqueray B, Hock MB, Skiles GL, Chow AT, Lee E. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis. J Clin Pharmacol. 2018 Jun;58(6):717-726. Abstract
  3. FDA. Etelcalcetide. Drug Summary. 2017 Full text (in our servers)
  4. EMA. Etelcalcetida Ficha técnica. 2016 Full text (in our servers)

Total visits

1,229

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child´s Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM